ArticleBlood2017
A subset of virus-specific CD161
Open access · bronzeAbstract read
In one paragraph
Article in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 28 citations in OpenAlex.
- Multi-omics insights for deciphering prognosis-related T cell subsets in hepatocellular carcinoma.Clinical and translational medicine · 2026Article
- MDR1 promotes CD8 T cell persistence in tumors and protects against cytotoxic chemotherapy.bioRxiv : the preprint server for biology · 2025Article
- Discovery of drug transporter inhibitors tied to long noncoding RNA in resistant cancer cells; a computational model -in silico- study.Frontiers in immunology · 2025Review
- Study of pathogenic T-helper cell subsets in Asian Indian patients with Takayasu arteritis.Immunologic research · 2024Article
- MDR1-EXPRESSING CD4Journal for immunotherapy of cancer · 2023Article
- Immune checkpoints represent a promising breakthrough in targeted therapy and prognosis of myelodysplastic syndrome.Heliyon · 2023Review
- Heparin and Heparin-Based Drug Delivery Systems: Pleiotropic Molecular Effects at Multiple Drug Resistance of Osteosarcoma and Immune Cells.Pharmaceutics · 2022Review
- LncRNA in tumorigenesis of non-small-cell lung cancer: From bench to bedside.Cell death discovery · 2022Review
- In-depth analysis of SARS-CoV-2-specific T cells reveals diverse differentiation hierarchies in vaccinated individuals.JCI insight · 2022Article
- Dissecting CD8+ T cell pathology of severe SARS-CoV-2 infection by single-cell immunoprofiling.Frontiers in immunology · 2022Article
- The cell-surface 5'-nucleotidase CD73 defines a functional T memory cell subset that declines with age.Cell reports · 2021Article
- Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia.International journal of molecular sciences · 2021Review
- Aging and CMV discordance are associated with increased immune diversity between monozygotic twins.Immunity & ageing : I & A · 2021Article
- Identification of six hub genes and analysis of their correlation with drug sensitivity in acute myeloid leukemia through bioinformatics.Translational cancer research · 2021Article
- Article
- Perplexing Role of P-Glycoprotein in Tumor Microenvironment.Frontiers in oncology · 2020Review
- CD8Frontiers in immunology · 2020Review
- CD161mBio · 2019Article
- Correlation of MDR1 gene polymorphism with propofol combined with remifentanil anesthesia in pediatric tonsillectomy.Oncotarget · 2018Article
- Impact of Aging on the Frequency, Phenotype, and Function of CD161-Expressing T Cells.Frontiers in immunology · 2018Article
Corrections and comments
- Commented on by
Authors and funding
20 authors at 4 institutions in 2 countries.
Abdullah AlsulimanStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX.
Muharrem MuftuogluStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX.
Ahmad KhoderDepartment of Hematology, Imperial College London, London, United Kingdom.
Yong-Oon AhnDivision of Hematology, Oncology, and Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN.
Rafet BasarStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX.
Michael R VernerisDivision of Hematology, Oncology, and Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN.
Pawel MuranskiHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; and.
A John BarrettHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; and.
Enli LiuStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX.
Li LiStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX.
Kate StringarisDepartment of Hematology, Imperial College London, London, United Kingdom.
Darius Armstrong-JamesFaculty of Medicine, National Heart and Lung Institute, Imperial College London, London, United Kingdom.
Hila ShaimStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX.
Kayo KondoStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX.
Nobuhiko ImahashiStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX.
Borje AnderssonStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX.
David MarinStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX.
Richard E ChamplinStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX.
Elizabeth J ShpallStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX.
Katayoun RezvaniStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX.
The University of Texas MD Anderson Cancer Center · USImperial College London · GBNational Institutes of Health · USUniversity of Minnesota · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MPR1-specific CB T cells for Patients with Myeloid MalignanciesP01CA148600 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KAUR, INDRESHPAL · 2011 to 2022
$24.4MHematopoietic Progenitor Cells- Cord BloodR01CA061508 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI REZVANI, KATY, SHPALL, ELIZABETH J · 1993 to 2020
$5.1MNCI NIH HHS P01 CA148600NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA061508
Abstract
The establishment of long-lived pathogen-specific T cells is a fundamental property of the adaptive immune response. However, the mechanisms underlying long-term persistence of antigen-specific CD4
Indexed as
Gene Expression Regulation, LeukemicImmunologic MemoryAntibiotics, AntineoplasticAntibodiesATP Binding Cassette Transporter, Subfamily BBiological TransportCD4 AntigensCD4-Positive T-LymphocytesCytomegalovirusDaunorubicinDrug Resistance, NeoplasmHumansImmunophenotypingInfluenza, HumanInfluenza VaccinesLeukemia, Myeloid, AcuteABCB1 protein, humanAntibiotics, AntineoplasticAntibodiesATP Binding Cassette Transporter, Subfamily BCD4 AntigensDaunorubicinInfluenza VaccinesKLRB1 protein, humanNK Cell Lectin-Like Receptor Subfamily BRhodamines
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.